title: Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
abstract: Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized application of immune therapeutics would increase the efficacy of immunotherapy. Here, we developed a method to predict and enhance the individual response to immunotherapy by using personalized mathematical models, constructed in the early phase of treatment. Our approach includes an iterative real-time in-treatment evaluation of patient-specific parameters from the accruing clinical data, construction of personalized models and their validation, model-based simulation of subsequent response to ongoing therapy, and suggestion of potentially more effective patient-specific modified treatment. Using a mathematical model of prostate cancer immunotherapy, we applied our model to data obtained in a clinical investigation of an allogeneic whole-cell therapeutic prostate cancer vaccine. Personalized models for the patients who responded to treatment were derived and validated by data collected before treatment and during its early phase. Simulations, based on personalized models, suggested that an increase in vaccine dose and administration frequency would stabilize the disease in most patients. Together, our findings suggest that application of our method could facilitate development of a new paradigm for studies of in-treatment personalization of the immune agent administration regimens (P-trials), with treatment modifications restricted to an approved range, resulting in more efficacious immunotherapies.
authors.affiliation: Institute for Medical BioMathematics, Bene Ataroth, Israel.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Kogan
authors.forename: Karin
authors.initials: K
authors.lastname: Halevi-Tobias
authors.forename: Moran
authors.initials: M
authors.lastname: Elishmereni
authors.forename: Stanimir
authors.initials: S
authors.lastname: Vuk-Pavlović
authors.forename: Zvia
authors.initials: Z
authors.lastname: Agur
mesh_terms: D000465:Algorithms; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003199:Computer Systems; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D018448:Models, Immunological; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D057285:Precision Medicine / Q000379:methods*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy
chemical_list: D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen